Tous Actualités
Suivre
Abonner Epigenomics AG

Epigenomics AG

Epigenomics AG Licenses Biomarker for Development of Prostate Cancer Test to Quest Diagnostics

Berlin, Germany and Seattle, WA, U.S.A. (euro adhoc) -

  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.
cooperations/Molecular Diagnostics
February 25,
2009 - Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer 
molecular diagnostics company, today announced that it has entered 
into a non-exclusive licensing agreement for its proprietary 
biomarker mGSTP1 with U.S.-based Quest Diagnostics Incorporated 
(NYSE: DGX), the world's leading provider of diagnostic testing, 
information and services.
Under the agreement, Quest Diagnostics has obtained rights to uses of
the GSTP1 DNA methylation biomarker (mGSTP1) to establish and 
commercialize a molecular- based laboratory-developed test that can 
help pathologists better diagnose prostate cancer based on testing of
a patient's tissue specimen. Financial terms were not disclosed.
Prostate cancer is the leading cause of cancer death in men in the 
U.S., with more than 230,000 cases diagnosed annually. Epigenomics 
and others have demonstrated that methylated DNA of the GSTP1 gene in
tissue may indicate the presence of prostate cancer. A test that 
detects the DNA methylation of the gene GSTP1 in tissue biopsies in 
combination with conventional histopathology may augment the accuracy
of prostate cancer diagnosis in particular in cases with suspicious 
but inconclusive histology findings or patients with elevated PSA but
repeatedly negative biopsies.
Quest Diagnostics' experience in DNA methylation diagnostics includes
offering tests for Prader-Willi and Angelman Syndromes, two 
neurologic epigenetic disorders that may be caused by faulty DNA 
methylation. In 2008, Quest Diagnostics licensed rights to use 
Epigenomics' proprietary colorectal cancer biomarker mSEPT9 to 
develop and validate a blood-based laboratory-developed test as an 
aid in the detection of colorectal cancer.
"We are pleased that Quest Diagnostics is expanding its menu of DNA 
methylation tests using our technologies and biomarkers. Quest 
Diagnostics has a strong record of innovation in diagnostics, 
including development of other DNA methylation diagnostic tests. They
also share our goal to develop technologies that will help physicians
achieve improved health outcomes for their patients through better 
diagnosis of prostate cancer and early detection of colorectal 
cancer", said Geert Nygaard, Chief Executive Officer of Epigenomics.
About Epigenomics
Epigenomics is a molecular diagnostics company with a focus on the 
development of novel products for cancer. Using DNA methylation 
biomarkers, Epigenomics' tests in development aim at diagnosing 
cancer at an early stage before symptoms occur and thereby may reduce
mortality from this dreaded disease.
Epigenomics' product pipeline contains a validated biomarker for the 
early detection of colorectal cancer in blood plasma, and further 
proprietary DNA methylation biomarkers at various stages of 
development for prostate and lung cancer detection in urine, blood 
and bronchial lavage specimens. Epigenomics' biomarker mSEPT9 for the
early detection of colorectal cancer in a simple blood sample 
demonstrated continuously highest performance in multiple clinical 
studies with in total about 3,500 individuals tested.
For development and global commercialization of in vitro diagnostic 
test products, Epigenomics pursues a non-exclusive partnering 
strategy. Strategic diagnostics industry partners include Abbott 
Molecular, Philips, Sysmex Corporation and Quest Diagnostics 
Incorporated for diagnostics test products and services, and QIAGEN 
N.V. for sample preparation solutions and research products.
Partners in the health care industry and the biomedical research 
community can access Epigenomics' portfolio of proprietary DNA 
methylation technologies and biomarkers protected by more than 150 
patent families through research products, Biomarker Services, IVD 
Development Collaborations, and Licensing. The company is 
headquartered in Berlin, Germany, and has a wholly owned subsidiary 
in Seattle, WA, U.S.A. For more information, please visit 
Epigenomics' website at www.epigenomics.com.
Epigenomics' legal disclaimer: This communication expressly or 
implicitly contains certain forward-looking statements concerning 
Epigenomics AG and its business. Such statements involve certain 
known and unknown risks, uncertainties and other factors which could 
cause the actual results, financial condition, performance or 
achievements of Epigenomics AG to be materially different from any 
future results, performance or achievements expressed or implied by 
such forward-looking statements. Epigenomics AG is providing this 
communication as of this date and does not undertake to update any 
forward- looking statements contained herein as a result of new 
information, future events or otherwise.
end of announcement                               euro adhoc

Further inquiry note:

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse München / free trade

Plus de actualités: Epigenomics AG
Plus de actualités: Epigenomics AG
  • 12.02.2009 – 08:01

    Epigenomics AG Successfully Places Shares at Premium in Capital Increase

    ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. companies/Diagnostics Berlin (euro adhoc) - 12. February 2009 - Epigenomics AG (Frankfurt, Prime Standard: ECX; ISIN: DE000A0BVT96) successfully placed all 2,671,088 new shares that were issued in an increase of the share capital against contribution ...